While cancer and COVID-19 share an elevated risk of thrombosis, with increased D-dimer levels (82), we show that the co-existence of neoplasia and COVID-19 inhibits the upregulation of the inflammatory biomarkers CRP and D-dimer, notoriously associated with COVID-19 severity (1, 19, 20), suggesting that the reduced expression of IL-6 observed in COV/CA PBMCs may result in reduced tissue factor levels (83) and thus in the concomitant reduction of D-dimer levels. Here, CRP is linked to cancer.